Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer

Romulo M. Brena, Carl Morrison, Sandya Liyanarachchi, David Jarjoura, Ramana V. Davuluri, Gregory A. Otterson, David Reisman, Selina Glaros, Laura J. Rush, Christoph Plass*

*Corresponding author for this work

Research output: Contribution to journalArticle

42 Scopus citations

Abstract

Background: Lung cancer is the leading cause of cancer-related death worldwide. Currently, tumor, node, metastasis (TNM) staging provides the most accurate prognostic parameter for patients with non-small cell lung cancer (NSCLC). However, the overall survival of patients with resectable tumors varies significantly, indicating the need for additional prognostic factors to better predict the outcome of the disease, particularly within a given TNM subset. Methods and Findings: In this study, we investigated whether adenocarcinomas and squamous cell carcinomas could be differentiated based on their global aberrant DNA methylation patterns. We performed restriction landmark genomic scanning on 40 patient samples and identified 47 DNA methylation targets that together could distinguish the two lung cancer subgroups. The protein expression of one of those targets, oligodendrocyte transcription factor 1 (OLIG1), significantly correlated with survival in NSCLC patients, as shown by univariate and multivariate analyses. Furthermore, the hazard ratio for patients negative for OLIG1 protein was significantly higher than the one for those patients expressing the protein, even at low levels. Conclusions: Multivariate analyses of our data confirmed that OLIG1 protein expression significantly correlates with overall survival in NSCLC patients, with a relative risk of 0.84 (95% confidence interval 0.77-0.91, p < 0.001) along with T and N stages, as indicated by a Cox proportional hazard model. Taken together, our results suggests that OLIG1 protein expression could be utilized as a novel prognostic factor, which could aid in deciding which NSCLC patients might benefit from more aggressive therapy. This is potentially of great significance, as the addition of postoperative adjuvant chemotherapy in T2N0 NSCLC patients is still controversial.

Original languageEnglish (US)
Pages (from-to)572-584
Number of pages13
JournalPLoS medicine
Volume4
Issue number3
DOIs
StatePublished - Mar 1 2007

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Brena, R. M., Morrison, C., Liyanarachchi, S., Jarjoura, D., Davuluri, R. V., Otterson, G. A., Reisman, D., Glaros, S., Rush, L. J., & Plass, C. (2007). Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer. PLoS medicine, 4(3), 572-584. https://doi.org/10.1371/journal.pmed.0040108